Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shiga University Of Medical Science maintains a company patent portfolio within the Biotechnology & Pharmaceuticals sector. Currently, the portfolio includes 1 pending office action. This workload is handled by 1 distinct examiner, JADHAO, SAMADHAN JAISING, who is also the busiest examiner with 1 busiest examiner pending action. All prosecution activity is localized within 1 distinct art unit.
For a practitioner, this concentration means the company's current USPTO engagement is limited to a specific channel. The 1 pending office action represents the entirety of the active pipeline. Navigating the Biotechnology & Pharmaceuticals field with 1 distinct examiner allows for a highly focused approach. However, it also means the portfolio's immediate growth depends on the resolution of the 1 busiest examiner pending action. Practitioners should tailor their strategy specifically to the tendencies of JADHAO, SAMADHAN JAISING to optimize outcomes within the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018442 | RECOMBINANT VACCINIA VIRUS | JADHAO, SAMADHAN JAISING | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18018442 | RECOMBINANT VACCINIA VIRUS | JADHAO, SAMADHAN JAISING | 1672 | §112 | Non-Final OA | — | Pending | Jan 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShiga University Of Medical Science has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samadhan Jaising Jadhao has the most, with 1 of Shiga University Of Medical Science's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
